EZR and non-small cell lung carcinoma: In the stratified analyses according to cancer type, over-expression of Ezrin yielded a worse OS in digestive system cancers (HR = 1.93, 95% CI: 1.31–2.85, P = 0.001), HNSCC (HR = 2.54, 95% CI: 1.85–3.49, P < 0.001), gynecologic cancer (HR = 1.86, 95%CI: 1.10–3.15, P = 0.021), osteosarcoma (HR = 3.16, 95% CI: 1.90–5.26, P < 0.001), hepatobiliary cancer (HR = 1.80, 95% CI: 1.27–2.56, P = 0.001), NSCLC (HR = 1.97, 95% CI: 1.23–3.18, P = 0.005) and a worse DSS/MFS in digestive cancers (HR = 3.03, 95% CI: 3.01–4.56, P < 0.001).